Rivus Pharmaceuticals Closes $132 Million Series B Financing To Advance Hu6 For The Treatment Of Obesity And Cardio-Metabolic Disorders
Amount Raised
$132 Million
Round Type
Series B
CharlottesvilleBiotechnologyHealth CareDescription
Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $132 million Series B financing led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital. This financing will further support clinical advancement of lead candidate HU6, a first-in-class Controlled Metabolic Accelerator (CMA) designed to treat cardio-metabolic disease by addressing obesity, a primary driver of disease.
Quick answer
Rivus Pharmaceuticals raised $132 Million in a Series B round, dated September 22, 2022. Rivus Pharmaceuticals is based in Charlottesville, Virginia, United States.
- How much did Rivus Pharmaceuticals raise?
- Rivus Pharmaceuticals raised $132 Million in a Series B round on September 22, 2022.
- What does Rivus Pharmaceuticals do?
- Rivus Pharmaceuticals, Inc., is dedicated to transforming the treatment of cardio-metabolic disease by advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators..
- Where is Rivus Pharmaceuticals based and how big is it?
- Rivus Pharmaceuticals is based in Charlottesville, Virginia, United States. Fundz records about 27 employees.
- Who are the decision-makers at Rivus Pharmaceuticals?
- Fundz holds 1 contact at Rivus Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Rivus Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Novadip Biosciences raised $39M (Funding Round) on November 4, 2022.
- Biocoat raised an undisclosed amount on November 2, 2022.
- Enzyre raised an undisclosed amount (Series A) on November 2, 2022.
- Carta Healthcare raised $20M (Series B) on November 2, 2022.
- Cerus raised an undisclosed amount (Grant) on November 2, 2022.
- Zenas BioPharma raised $184M on November 2, 2022.
Who to call at Rivus Pharmaceuticals, and when
A new round usually means Rivus Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Rivus Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Rivus Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Rivus Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Rivus Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansRivus Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.